These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 17427199

  • 1. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
    Bessard A, Frémin C, Ezan F, Coutant A, Baffet G.
    J Cell Physiol; 2007 Aug; 212(2):526-36. PubMed ID: 17427199
    [Abstract] [Full Text] [Related]

  • 2. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 3. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.
    Bessard A, Frémin C, Ezan F, Fautrel A, Gailhouste L, Baffet G.
    Oncogene; 2008 Sep 11; 27(40):5315-25. PubMed ID: 18521085
    [Abstract] [Full Text] [Related]

  • 4. EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells.
    Baek MK, Kim MH, Jang HJ, Park JS, Chung IJ, Shin BA, Ahn BW, Jung YD.
    Oncol Rep; 2008 Dec 11; 20(6):1569-75. PubMed ID: 19020743
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
    Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, Henklein P, Biskup C, Westermann M, Hollenberg MD, Settmacher U.
    J Cell Physiol; 2007 Jun 11; 211(3):699-707. PubMed ID: 17323377
    [Abstract] [Full Text] [Related]

  • 6. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition.
    Matsumoto K, Okano J, Nagahara T, Murawaki Y.
    Int J Oncol; 2006 Dec 11; 29(6):1501-8. PubMed ID: 17088989
    [Abstract] [Full Text] [Related]

  • 7. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A, Xue M, Jackson C, Smith RC.
    Int J Biochem Cell Biol; 2009 Dec 11; 41(8-9):1731-8. PubMed ID: 19433314
    [Abstract] [Full Text] [Related]

  • 8. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K.
    Int J Oncol; 2006 Apr 11; 28(4):807-14. PubMed ID: 16525628
    [Abstract] [Full Text] [Related]

  • 9. uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line.
    Yoon SY, Lee YJ, Seo JH, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS.
    Cell Res; 2006 Jan 11; 16(1):75-81. PubMed ID: 16467878
    [Abstract] [Full Text] [Related]

  • 10. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J, Yip-Schneider M, Albertin F, Wiesenauer C, Wang Y, Schmidt CM.
    J Surg Res; 2008 Dec 11; 150(2):219-26. PubMed ID: 18468633
    [Abstract] [Full Text] [Related]

  • 11. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A, Kassis J, Kharait S, Kloeker S, Manos E, Jones DA, Wells A.
    Exp Cell Res; 2004 Sep 10; 299(1):91-100. PubMed ID: 15302576
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
    Besch R, Berking C, Kammerbauer C, Degitz K.
    Cell Death Differ; 2007 Apr 10; 14(4):818-29. PubMed ID: 17110957
    [Abstract] [Full Text] [Related]

  • 13. Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway.
    Péqueux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG.
    Endocr Relat Cancer; 2004 Dec 10; 11(4):871-85. PubMed ID: 15613460
    [Abstract] [Full Text] [Related]

  • 14. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
    Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, Lo CM, Poon RT, Fan ST.
    Carcinogenesis; 2008 Nov 10; 29(11):2096-105. PubMed ID: 18765415
    [Abstract] [Full Text] [Related]

  • 15. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 10; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 16. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA.
    Oncogene; 2007 Feb 08; 26(6):813-21. PubMed ID: 16909118
    [Abstract] [Full Text] [Related]

  • 17. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation.
    Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng IO.
    Cancer Res; 2007 Apr 15; 67(8):3601-8. PubMed ID: 17440071
    [Abstract] [Full Text] [Related]

  • 18. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
    Ciccarelli C, Marampon F, Scoglio A, Mauro A, Giacinti C, De Cesaris P, Zani BM.
    Mol Cancer; 2005 Dec 13; 4():41. PubMed ID: 16351709
    [Abstract] [Full Text] [Related]

  • 19. Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
    Wang Z, Ge L, Wang M, Carr BI.
    J Cell Physiol; 2006 Jul 13; 208(1):133-40. PubMed ID: 16596619
    [Abstract] [Full Text] [Related]

  • 20. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.